Last reviewed · How we verify
NCT05048472: EAPoC-VL
East Africa Point of Care Viral Load Study
NA trial testing Abbott HIV-1/2 VL Point of care Device in HIV in 956 participants. Completed in 30 April 2025.
30 April 2025
Quick facts
| Lead sponsor | MRC/UVRI and LSHTM Uganda Research Unit |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 956 |
| Start date | 19 August 2022 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 7 locations across Rwanda, Kenya, Tanzania, Uganda |
Drugs / interventions tested
- Abbott HIV-1/2 VL Point of care Device
Conditions studied
- HIV — all drugs for HIV →
- Viral Load — all drugs for Viral Load →
- Point of Care Monitoring — all drugs for Point of Care Monitoring →
Sponsor
MRC/UVRI and LSHTM Uganda Research Unit — full company profile →
Who can join
Adults 6 Months to 24, any sex, with HIV or Viral Load. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of EAPoC-VL project is to examine the feasibility, acceptability, and effectiveness of using point of care viral load (PoC VL) monitoring to improve viral load suppression among children, adolescents and young people (age ≤24 years) living with HIV in Kenya, Rwanda, Tanzania and Uganda.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05048472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other MRC/UVRI and LSHTM Uganda Research Unit trials
Trials by the same sponsor.
- NCT06133686 — Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa · Phase 3 · not yet recruiting
- NCT06093646 — Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda · NA · unknown
- NCT05516602 — Improving HIV Prevention Among Adolescent Girls and Young Women (AGYW) in Uganda · NA · completed
- NCT05487079 — Identification and Characterization of Diabetes in Low-resource Populations · unknown
- NCT04934111 — Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19 · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05048472 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MRC/UVRI and LSHTM Uganda Research Unit
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05048472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing